Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122896 · ClinicalTrials.gov registry record · Early Phase 1
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
A Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 5,000
- Enrollment target
- 2
- Study locations
NCT06122896 is a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 5,000 participants, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT06122896, a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
Conditions Studied
Interventions
- OTHER Screening Blood Tests
- DIAGNOSTIC_TEST Endoscopic Ultrasound
- COMBINATION_PRODUCT Magnetic Resonance Imaging
- COMBINATION_PRODUCT Magnetic Resonance Cholangiopancreatography
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2041-10-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06122896
The ClinicalTrials.gov registry entry for NCT06122896 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Screening Blood Tests is the first listed.
NCT06122896 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06122896 about?
NCT06122896 is a clinical study titled "Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals". The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
What is the current status of trial NCT06122896?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 5,000 participants. The study started on 2023-11-21. Estimated completion is 2041-10-31.
What conditions does trial NCT06122896 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC.
What interventions are being tested in trial NCT06122896?
The interventions under investigation include: Screening Blood Tests (OTHER), Endoscopic Ultrasound (DIAGNOSTIC_TEST), Magnetic Resonance Imaging (COMBINATION_PRODUCT), Magnetic Resonance Cholangiopancreatography (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06122896?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122896 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Lidocaine Infusion in Pancreatic Cancer
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.